Drug
BI 4015092
BI 4015092: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 4015092 NCT07926334 | Phase 1 | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation |
Latest
No recent events.
Follow BI 4015092 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.